These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27469180)

  • 1. Respiratory System Disease.
    Goetz DM; Singh S
    Pediatr Clin North Am; 2016 Aug; 63(4):637-59. PubMed ID: 27469180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary infections in patients with cystic fibrosis.
    Rajan S; Saiman L
    Semin Respir Infect; 2002 Mar; 17(1):47-56. PubMed ID: 11891518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Respiratory disease in cystic fibrosis: from physiopathology to therapy. Kinesitherapy and pulmonary transplantation excluded].
    Reynaud-Gaubert M
    Rev Mal Respir; 1999 Sep; 16(4):495-509. PubMed ID: 10549060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deleterious impact of Pseudomonas aeruginosa on cystic fibrosis transmembrane conductance regulator function and rescue in airway epithelial cells.
    Trinh NT; Bilodeau C; Maillé É; Ruffin M; Quintal MC; Desrosiers MY; Rousseau S; Brochiero E
    Eur Respir J; 2015 Jun; 45(6):1590-602. PubMed ID: 25792634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiology and management of pulmonary infections in cystic fibrosis.
    Gibson RL; Burns JL; Ramsey BW
    Am J Respir Crit Care Med; 2003 Oct; 168(8):918-51. PubMed ID: 14555458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cystic fibrosis lung disease and its management].
    Hidaka N; Hidaka Y
    Nihon Rinsho; 1999 Sep; 57(9):2139-44. PubMed ID: 10497420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection.
    Ziedalski TM; Kao PN; Henig NR; Jacobs SS; Ruoss SJ
    Chest; 2006 Oct; 130(4):995-1002. PubMed ID: 17035430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis.
    Bienvenu T; Sermet-Gaudelus I; Burgel PR; Hubert D; Crestani B; Bassinet L; Dusser D; Fajac I
    Am J Respir Crit Care Med; 2010 May; 181(10):1078-84. PubMed ID: 20167849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How mutant CFTR may contribute to Pseudomonas aeruginosa infection in cystic fibrosis.
    Pier GB; Grout M; Zaidi TS; Goldberg JB
    Am J Respir Crit Care Med; 1996 Oct; 154(4 Pt 2):S175-82. PubMed ID: 8876538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression of early structural lung disease in young children with cystic fibrosis assessed using CT.
    Mott LS; Park J; Murray CP; Gangell CL; de Klerk NH; Robinson PJ; Robertson CF; Ranganathan SC; Sly PD; Stick SM;
    Thorax; 2012 Jun; 67(6):509-16. PubMed ID: 22201161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Gene therapy of respiratory diseases: a new era?].
    Chinet T
    Rev Mal Respir; 1995; 12(6):515-6. PubMed ID: 8677343
    [No Abstract]   [Full Text] [Related]  

  • 13. Fixing cystic fibrosis CFTR with correctors and potentiators. Off to a good start.
    Elborn JS
    Thorax; 2012 Jan; 67(1):4-5. PubMed ID: 22058188
    [No Abstract]   [Full Text] [Related]  

  • 14. Cystic fibrosis: toward personalized therapies.
    Ikpa PT; Bijvelds MJ; de Jonge HR
    Int J Biochem Cell Biol; 2014 Jul; 52():192-200. PubMed ID: 24561283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship of chronic mucin secretion to airway disease in normal and CFTR-deficient mice.
    Cressman VL; Hicks EM; Funkhouser WK; Backlund DC; Koller BH
    Am J Respir Cell Mol Biol; 1998 Dec; 19(6):853-66. PubMed ID: 9843919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic fibrosis transmembrane conductance regulator (CFTR)-mediated residual chloride secretion does not protect against early chronic Pseudomonas aeruginosa infection in F508del homozygous cystic fibrosis patients.
    Derichs N; Mekus F; Bronsveld I; Bijman J; Veeze HJ; von der Hardt H; Tummler B; Ballmann M
    Pediatr Res; 2004 Jan; 55(1):69-75. PubMed ID: 14605249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cystic fibrosis in a woman aged seventy].
    Ras JE; van Velzen E; van Berkhout FT; van den Brand JJ
    Ned Tijdschr Geneeskd; 2010; 154():A1342. PubMed ID: 20619026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cystic fibrosis transmembrane conductance regulator-mRNA delivery: a novel alternative for cystic fibrosis gene therapy.
    Bangel-Ruland N; Tomczak K; Fernández Fernández E; Leier G; Leciejewski B; Rudolph C; Rosenecker J; Weber WM
    J Gene Med; 2013; 15(11-12):414-26. PubMed ID: 24123772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-classic cystic fibrosis associated with D1152H CFTR mutation.
    Burgel PR; Fajac I; Hubert D; Grenet D; Stremler N; Roussey M; Siret D; Languepin J; Mely L; Fanton A; Labbé A; Domblides P; Vic P; Dagorne M; Reynaud-Gaubert M; Counil F; Varaigne F; Bienvenu T; Bellis G; Dusser D
    Clin Genet; 2010 Apr; 77(4):355-64. PubMed ID: 19843100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis.
    Teichgräber V; Ulrich M; Endlich N; Riethmüller J; Wilker B; De Oliveira-Munding CC; van Heeckeren AM; Barr ML; von Kürthy G; Schmid KW; Weller M; Tümmler B; Lang F; Grassme H; Döring G; Gulbins E
    Nat Med; 2008 Apr; 14(4):382-91. PubMed ID: 18376404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.